NY-ESO-1-Specific CD8 T Cell Response in NY-ESO-1 Seropositive Metastatic Melanoma Patients Treated with Ipilimumab Correlates with Clinical Benefit

被引：0

作者：

Yuan, Jianda ^{[1
]}

Gnjatic, Sacha ^{[2
]}

Adamow, Matthew ^{[1
]}

Ginsberg, Brian ^{[1
]}

Rasalan, Teresa S. ^{[1
]}

Ritter, Erika ^{[2
]}

Gallardo, Humilidad F. ^{[1
]}

Xu, Yinyan ^{[1
]}

Pogoriler, Evelina ^{[3
]}

Panageas, Katherine S. ^{[3
]}

Yang, Arvin ^{[1
,3
]}

Terzulli, Stephanie ^{[1
,3
]}

Ritter, Gerd ^{[2
]}

Old, Lloyd J. ^{[2
]}

Allison, James P. ^{[1
]}

Wolchok, Jedd D. ^{[1
,3
]}

机构：

[1] Ludwig Ctr Canc Immunotherapy, New York, NY USA

[2] Ludwig Inst Canc Res, NY Branch, New York, NY USA

[3] MSKCC, New York, NY USA

来源：

JOURNAL OF IMMUNOTHERAPY | 2010年 / 33卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：913 / 914

页数：2

共 50 条

[21] Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
Tsuji, Kazuhide
Hamada, Toshitada
Uenaka, Akiko
Wada, Hisashi
Sato, Eiichi
Isobe, Midori
Asagoe, Kenji
Yamasaki, Osamu
Shiku, Hiroshi
Ritter, Gerd
Murphy, Roger
Hoffman, Eric W.
Old, Lloyd J.
Nakayama, Eiichi
Iwatsuki, Keiji
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (10) : 1429 - 1437
[22] A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma
Ebert, Lisa M.
MacRaild, Sarah E.
Zanker, Damien
Davis, Ian D.
Cebon, Jonathan
Chen, Weisan
PLOS ONE, 2012, 7 (10):
[23] Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers
Jäger, E
Gnjatic, S
Nagata, Y
Stockert, E
Jäger, D
Karbach, J
Neumann, A
Rieckenberg, J
Chen, YT
Ritter, G
Hoffman, E
Arand, M
Old, LJ
Knuth, A
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) : 12198 - 12203
[24] T Cells Targeting NY-ESO-1 and Melan-A Are Prognostic in Melanoma
不详
CANCER DISCOVERY, 2012, 2 (06)
[25] Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
Gong, Wenjie
Wang, Lei
Stock, Sophia
Ni, Ming
Schubert, Maria-Luisa
Neuber, Brigitte
Kleist, Christian
Huckelhoven-Krauss, Angela
Wu, Depei
Muller-Tidow, Carsten
Schmitt, Anita
Shiku, Hiroshi
Schmitt, Michael
Sellner, Leopold
CELLS, 2021, 10 (01) : 1 - 14
[26] No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
Goff, Stephanie L.
Robbins, Paul F.
El-Gamil, Mona
Rosenberg, Steven A.
JOURNAL OF IMMUNOTHERAPY, 2009, 32 (08) : 884 - 885
[27] Multiepitope CD8+ T cell response to an NY-ESO-1 peptide vaccine results in imprecise tumor targeting
Dutoit, V
Taub, RN
Papadopoulos, KP
Talbot, S
Keohan, ML
Brehm, M
Gnjatic, S
Harris, PE
Bisikirska, B
Guillaume, P
Cerottini, JC
Hesdorffer, CS
Old, LJ
Valmori, D
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (12): : 1813 - 1822
[28] NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen
Zelba, Henning
Weide, Benjamin
Garbe, Claus
Pawelec, Graham P.
Derhovanessian, Evelyna
CANCER RESEARCH, 2010, 70
[29] A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
Slingluff, Craig L., Jr.
Zarour, Hassane M.
Tawbi, Hussein Abdul-Hassan
Kirkwood, John M.
Postow, Michael A.
Friedlander, Philip
Devoe, Craig E.
Gaughan, Elizabeth M.
Mauldin, Ileana S.
Olson, Walter C., Jr.
Smith, Kelly T.
Macri, Mary J.
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph
Wolchok, Jedd D.
ONCOIMMUNOLOGY, 2021, 10 (01):
[30] Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.
Klein, Oliver
Davis, Ian D.
McArthur, Grant A.
Haydon, Andrew Mark
Parente, Phillip
Dimopoulos, Nektaria
Jackson, Heather
Maraskovsky, Eugene
Hopkins, Wendie
Stan, Rodica
Chen, Weisan
Cebon, Jonathan S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →